SCM
ELDN icon

Sterling Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Sterling Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06K Sell
270
-2,074
-88% -$7.54K ﹤0.01% 3117
2026
Q1 		$7.22K Sell
2,344
-1,315
-36% -$3.1K ﹤0.01% 2554
2025
Q4 		$5.53K Buy
3,659
+15
+0.4% +$36 ﹤0.01% 2863
2025
Q3 		$9.44K Buy
3,644
+2,151
+144% +$6.29K ﹤0.01% 2512
2025
Q2 		$4.05K Buy
+1,493
New +$4.48K ﹤0.01% 2626

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Sterling Capital Management's ELDN Position: Q2 2026 in Review

Sterling Capital Management reduced its Eledon Pharmaceuticals (ELDN) stake by 88% in Q2 2026, selling an estimated $7.54K and leaving 270 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3117.

Sterling Capital Management first reported a position in ELDN in Q2 2025 and has held it in 5 quarters since. The position peaked at $9.44K in Q3 2025. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Sterling Capital Management held 270 shares of Eledon Pharmaceuticals worth $1.06K as of Q2 2026.
  • Sterling Capital Management sold 2,074 Eledon Pharmaceuticals shares in Q2 2026, an estimated $7.54K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3117 holding.
  • Sterling Capital Management first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Eledon Pharmaceuticals position peaked at $9.44K in Q3 2025.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.